Creating new hope, and improving patient outcomes, in infectious diseases and cancer
GEN-Y Biologics was formed in 2020 to license, productise and take to market superior antibody technologies derived from state-of-the-art technological platforms developed with the National University of Singapore’s highly prestigious Life Sciences Institute.
Their unique antibody discovery platform for fully human antibodies, together with advanced antibody and protein engineering, provides a pipeline of highly specific biologics for therapeutic and diagnostic use.
Assoc Prof Paul MacAry, PhD
Founding Scientist & Senior Scientific Advisor
- Associate Professor and Director, Life Sciences Institute, National University of Singapore
- Co-Chair & Co-Director, Singapore-Hebrew University of Jerusalem Research Alliance
- Expert in Antibody Technologies & Infectious Diseases
- PhD King’s College London
Prof William Haseltine, PhD
Scientific Advisor
- Chairman and President of ACCESS Health International
- Expert in Infectious Diseases (HIV/AIDS, COVID-19)
- Founder of >7 Biotech Companies
- Former Professor, Harvard Medical School
- Former Presidential Advisor, HIV/AIDS, to US and French Governments
- PhD Harvard University
Prof Jeffrey Almond, PhD FMedSci
Scientific Advisor
- Visiting Professor of Microbiology, University of Oxford
- Chairman, Virion Health
- Science Advisory Board Member National Institute for Biological Standards and Control, UK
- Work-Group Chair, UK Government Vaccine Network
- Former Head of Vaccine R&D, Sanofi Pasteur
- Former Professor, University of Reading
- PhD University of Cambridge
Graham Almond
Director
- Managing Director, Lumicara Pte Ltd
- Former Vice-President SE Asia, Global Operations, Sanofi
- Former SEA PhRMA head
- BSc University of Manchester
Mary Kozma
Product Development & Manufacturing
- Former Manager NUS, Institute of Life Sciences Antibody Engineering Programme
- 30+ years research and laboratory management experience
- Researcher at Imperial College, University of London; Royal Free Hospital Medical School, University of London; Imperial Cancer Research Fund, London
- BSc University of Edinburgh
Kenneth Tan
Co-Founder, Chairman of the Board and Acting CFO
- Managing Partner & Managing Director of Southern Capital
- Co-Founder and EVP of Cassis International
- Former Assistant VP at GIC
- BA (First Class Honours), Cambridge University
Xiang Liang (XL) Lin
Co-Founder
- Deputy CEO, ESCO Lifesciences Group
- Founding CEO, ESCO Aster
- Early Stage Biotech Investor
- BSc University of Sydney
Suong Hong Nguyen
Co-Founder, Executive Director and CBO
- Managing Director of Victory Global Holdings
- Founding member of Asia Capital Enterprises, GC Millennium Group, Starise Investments and Cathay Investment Fund
- Established Equity Derivatives across European Markets at Morgan Stanley
- MBA Harvard University, Post-doctorate INSEAD